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A programmed cell death pathway in the malaria
parasite Plasmodium falciparum has general features
of mammalian apoptosis but is mediated by clan
CA cysteine proteases
J-H Ch’ng1, SR Kotturi2, AG-L Chong3, MJ Lear2,4 and KS-W Tan*,1,3
Several recent discoveries of the hallmark features of programmed cell death (PCD) in Plasmodium falciparum have presented
the possibility of revealing novel targets for antimalarial therapy. Using a combination of cell-based assays, flow cytometry and
fluorescence microscopy, we detected features including mitochondrial dysregulation, activation of cysteine proteases and
in situ DNA fragmentation in parasites induced with chloroquine (CQ) and staurosporine (ST). The use of the pan-caspase
inhibitor, z-Val-Ala-Asp-fmk (zVAD), and the mitochondria outer membrane permeabilization (MOMP) inhibitor, 4-hydroxy-
tamoxifen, enabled the characterization of a novel CQ-induced pathway linking cysteine protease activation to downstream
mitochondrial dysregulation, amplified protease activity and DNA fragmentation. The PCD features were observed only at high
(lM) concentrations of CQ. The use of a new synthetic coumarin-labeled chloroquine (CM-CQ) showed that these features may
be associated with concentration-dependent differences in drug localization. By further using cysteine protease inhibitors z-Asp-
Glu-Val-Asp-fmk (zDEVD), z-Phe-Ala-fmk (zFA), z-Phe-Phe-fmk (zFF), z-Leu-Leu-Leu-fmk (zLLL), E64d and CA-074, we were able
to implicate clan CA cysteine proteases in CQ-mediated PCD. Finally, CQ induction of two CQ-resistant parasite strains, 7G8 and
K1, reveals the existence of PCD features in these parasites, the extent of which was less than 3D7. The use of the chemoreversal
agent verapamil implicates the parasite digestive vacuole in mediating CQ-induced PCD.
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The most deadly of the four clinically relevant malaria
parasites, Plasmodium falciparum, continues to kill an
estimated one million people annually.1 Although current
drugs can combat the disease, the increase in resistance to
these medicines makes it crucial for new leads to be
uncovered, such that new therapeutic initiatives will be one
step ahead of disease progression.2 One pathway yet to be
thoroughly explored for antimalarial development is that of
programmed cell death (PCD).
Recent reports highlight the existence of PCD features in
unicellular organisms including Blastocystis, Leishmania,
trypanosomes, Saccharomyces cerevisiae and Trichomonas
vaginalis.3 Indeed, accounts of PCD in P. falciparum4 and
the rodent malaria parasite P. berghei5 have been docu-
mented, as featured by the fragmentation of DNA and a
loss of mitochondria membrane potential. However, other
reports suggest that P. falciparum does not undergo
PCD.6–7
Besides inconclusive cell death features in the malaria
pathogen, there is a lack of evidence for a clear pathway
linking such features. In addition, PCD pathway mediators
have yet to be identified. Some studies have made use of
caspase inhibitors or substrates to suggest the involvement of
clan CD cysteine protease mediators such as metacaspase-
orthologs8 or caspase 3-like proteases.9 These assays,
however, have been shown to be nonspecific and do not
reliably discriminate between the clan CA and CD cysteine
proteases.10–11
Our study began by characterizing the PCD pathway of
P. falciparum. First, we conducted three cell-based assays
and detected mitochondrial dysregulation, cysteine protease
activation and DNA fragmentation in both CQ- and
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ST-induced parasites. Second, the mitochondria outer mem-
brane permeabilization (MOMP) inhibitor, 4-hydroxytamox-
ifen, and pan-caspase inhibitor, z-Val-Ala-Asp-fmk (zVAD),
were used to determine the order in which these PCD features
occurred. Interestingly, the sequence of events in CQ-induced
parasites showed a striking resemblance to the classical
mammalian apoptotic pathway even in the absence of
classical apoptotic machinery. Third, owing to the cross-
reactive nature of fluoromethylketone (fmk) inhibitors, clan
CA-specific protease inhibitors E64d and CA-074 were used
and showed that clan CA cysteine proteases are crucial
mediators in the CQ-induced PCD pathway. Clan CA
proteases, in particular the cathepsins and calpains, have
already been implicated in protozoan PCD.12–15 As such, the
discovery of clan CA proteases as PCD mediators in
P. falciparum presents a clear new target of therapeutic
intervention for future antimalarial design. Finally, the exis-
tence of CQ-induced PCD was shown in drug-resistant strains
7G8 and K1, and the importance of CQ’s lysosomotropic
nature in triggering these features is discussed.
Results
Mitochondrial membrane potential assay. The
accumulation of JC-1 J-aggregates in uninduced cells
showed that about 90% of the parasites contained
functional mitochondrion with transmembrane potential
(Dcm) (Figure 1a and c). Confocal microscopy confirmed
the specificity of the aggregated mitochondrial stain
(Figure 1b). Treatment with CQ or ST caused a significant
decline in this proportion to approximately 69 and 75%,
respectively (Figure 1a).
Pretreatment of parasite culture with 4-hydroxy-tamoxifen
(4HT) inhibited CQ-induced MOMP almost entirely, returning
the proportion of JC1-positive cells to B90% (Figure 1a).
However, 4HT was unable to exert a similar protective effect
for ST-induced parasites, suggesting that ST-induced
decrease in JC-1 values was independent of MOMP.
Pan-caspase inhibitor, zVAD, was similarly able to rescue
CQ-induced cells from loss of Dcm but was unable to protect
cells from ST-induced JC-1 loss (Figure 1a). Almost 90% of
CQ-induced cells pretreated with zVAD were JC1-positive
compared with 77% of ST-induced cells. This suggests
that the activity of cysteine proteases is upstream of MOMP
in CQ-induced cells.
The use of 4HT and zVAD in combination did not rescue
ST-induced cells from JC-1 loss, whereas CQ-induced cells
were completely rescued (Figure 1a).
Cysteine protease activity. In parasitized erythrocytes,
high background staining within the erythrocyte (data not
shown) deemed it necessary for parasites to be enriched by
saponin-lysis of the host erythrocyte such that fluorescence
of the parasite itself could be clearly recorded. In uninduced
parasites, a basal level of CaspaTag activity was detected in
10% of the cells (Figure 2a and c). This proportion increased
significantly on CQ and ST induction to 34 and 32%,
respectively. The retention of CaspaTag in a greater
proportion of CQ- and ST-induced parasites suggested that
the pan-caspase stain was bound to cysteine proteases that
had been activated by the drug treatments.
Preincubation of the parasite culture with zVAD reduced the
basal proportion of uninduced cells that are CaspaTag-
positive to 5% and suppressed CQ-induced CaspaTag
binding to below 10% (Figure 2a). Interestingly, zVAD did
not reduce the proportion of CaspaTag-positive cells after ST
treatment.
Even in the absence of CQ and ST, 4HT increased the
proportion of CaspaTag-positive cells slightly to 17%
(Figure 2a). Moreover, 4HT increased the proportion of
CaspaTag-positive cells in ST-treated cultures from 32 to
80%, suggesting synergism between 4HT and ST on the
parasite. This synergistic effect was not preventable by zVAD
treatment. Despite this inherent toxicity, 4HT reduced
CaspaTag binding in CQ-induced cells from 34 to 15%,
showing clearly that MOMP is essential for cysteine protease
activity in CQ-induced parasites.
In situ DNA fragmentation. As with the CaspaTag assay,
parasitized cultures treated with various conditions were
saponin-enriched just before TUNEL staining and gated in an
identical manner. There was an increase in the proportion of
TUNEL-positive cells from 10 to 27% and 56% in parasites
induced by CQ and ST, respectively, indicating that these
two drugs induced in situ DNA fragmentation in parasites
(Figure 3a and c).
Pretreatment of parasite cultures with 4HT alone resulted in
an increase in TUNEL-positive cells to 22.5% (Figure 3a).
Moreover, 4HT was ineffective in reducing the percentage of
TUNEL-positive cells in both CQ- and ST-treated cultures,
possibly owing to its inherent toxicity.
Pretreatment with zVAD, however, significantly reduced the
TUNEL-positive population in CQ-induced but not in
ST-induced cultures (Figure 3a). This suggested that zVAD
was able to effectively inhibit the pathway leading to in situ
DNA fragmentation in CQ-induced parasites but not in ST-
induced populations.
In double inhibition studies, the proportion of CQ-induced
TUNEL-positive cells decreased but the toxic effects of 4HT
were still observable in the non-induced cultures (Figure 3a).
ST-induced cultures remained highly TUNEL-positive even
when inhibitors were used in combination.
Figure 1 JC-1 staining of infected RBCs shows loss of mitochondrial membrane potential (Dcm) in Plasmodium falciparum parasites treated with drugs. (a) The proportion
of JC1-positive parasites are represented in a bar chart to show populations pretreated with vehicle control, 10 mM 4-hydroxytamoxifen (4HT) or 50mM z-VAD-fmk (zVAD) and
subjected to 8-h treatment with vehicle control , 30mM chloroquine or 10mM of staurosporine . Data represent means±S.E. (AvB, AvC and BvF, Po0.001; BvE,
Po0.01; BvD, Po0.05; N¼ 4) In each experiment, the full set of treatment conditions were carried out concurrently with the same batch of cells. Percentages represent
ratios normalized to the healthy control population in each experiment. (b) Confocal microscopy of an uninfected erythrocyte and a trophozoite-infected erythrocyte (adjoining
panels) with JC-1 monomer (green) accumulation in the parasite cytoplasm and J-aggregate (red) in the rod-shaped mitochondria of the same cell. (c) Flow cytometry
histograms showing the gating of JC1(red)-positive and JC1(green)-positive populations, the ratio of which represents the JC1-positive population
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As CQ-induced parasites displayed clearer PCD induction
and inhibition in MOMP, cysteine protease activity and in situ
DNA fragmentation assays, we focused on the characteriza-
tion of the CQ-induced pathway and its mediators.
Time course experiments with CaspaTag and JC-1. Time
course experiments on CQ-induced parasites showed that a
significant decrease in JC-1-positive cells occurred after
4 h of drug administration in contrast to the increase
in CaspaTag-positive cells that was significant only after 6 h
(Figure 4). This suggests that mitochondrial dysregulation
is an early-onset feature of PCD, which precedes the
activation of cysteine proteases. As it was also shown that
zVAD is able to prevent MOMP, the activity of cysteine
proteases must be essential for the loss of Dcm to take place.
We therefore posit that a small increase in protease activity
leads to mitochondrial permeabilization, which then amplifies
the protease cascade in a positive feedback loop.
Preparation and validation of fluorescent-labeled
chloroquine. To determine the localization of chloroquine
(CQ), we synthesized a CQ analog conjugated to biologically
benign coumarin (CM) fluorophore.16 HPLC and NMR
analyses indicated that coumarin-labeled chloroquine
(CM-CQ) was synthesized with excellent purity of 98%
(Supplementary data, Figure S11–13). To ascertain the
biological efficacy of CM-CQ, IC50 curves were measured
and the inhibitory efficiencies of the CQ compounds
determined (Supplementary data, Figure S1A). In addition,
the effect of varying CM-CQ concentrations on JC-1 assay
was also measured (Supplementary data, Figure S2). These
assays show that CM-CQ behaves similar to CQ in parasite
killing and inducing MOMP, but with about 10-fold less
efficacy.
Dose-dependent effect of CQ. JC-1 and CaspaTag assays
were used to investigate PCD features at different
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Figure 2 CaspaTag staining of saponin-enriched Plasmodium falciparum parasites shows the activation of cysteine proteases after incubation with drugs. (a) Percentage
of CaspaTag-positive cells pretreated with vehicle control, 10mM 4-hydroxytamoxifen (4HT) or 50 mM z-VAD-fmk (zVAD) and subjected to 8 h treatment with vehicle
control , 30mM chloroquine or 10mM of staurosporine . In each experiment, the full set of treatment conditions were carried out concurrently with the same batch of
cells. Data represent means±S.E. (AvB, AvC, BvG, AvD, CvF and BvE, Po0.001; N¼ 3) (b) Fluorescent microscopy and (c) flow cytometry histograms show the increase in
proportion of CaspaTag-positive cells after chloroquine treatment, with and without 30min preincubation with zVAD or 4HT
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concentrations of CQ (Figure 5a). At low nanomolar
concentrations, there were basal levels of PCD features
but at micromolar concentrations of CQ, there was a large
increase in the proportion of cells displaying MOMP and
activation of cysteine proteases. Confocal microscopy
revealed a dose-dependent relocalization of labeled CQ
from the DV at nanomolar concentrations to the cytoplasm at
micromolar concentrations (Figure 5b and Supplementary
Data, Figure S3).
Necrosis control experiments. To exclude the possibility
that the CQ-induced PCD is an unregulated necrotic death,
parasitized cultures were subjected to sodium azide and
501C treatments in the presence or absence of zVAD
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Figure 3 TUNEL staining of saponin-enriched Plasmodium falciparum parasites shows in situ DNA fragmentation occurring after incubation with drugs. (a) Percentage of
TUNEL-positive cells pretreated with vehicle control, 10 mM 4-hydroxytamoxifen (4HT) or 50 mM z-VAD-fmk (zVAD), subject to 8 h treatment with vehicle control , 30mM
chloroquine or 10mM of staurosporine . In each experiment, the full set of treatment conditions were carried out concurrently with the same batch of cells. Data represent
means±S.E. (AvC, Po0.001; AvB, AvD and BvE, Po0.01; BvG, Po0.05; AvF, P¼ 0.073; N¼ 3) (b) Fluorescent microscopy and (c) flow cytometry histograms show the
increase in proportion of TUNEL-positive cells after CQ and ST treatments, with and without 30min preincubation with zVAD and/or 4HT. For TUNEL-labeled cells, the quick
fading of fluorescence deemed it necessary for cell clusters to be observed instead of single-cell suspensions
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(Figure S4–S6). Both treatments resulted in a different cell
death profile from the CQ-induced pathway and zVAD was
unable to inhibit these features. Heat treatment altered JC-1
background staining of the erythrocytes and therefore data
were excluded.
Effect of different inhibitors on CaspaTag
binding. Owing to the well-documented nonspecific bind-
ing of zVAD to both clan CD and CA proteases10–11,14,17
coupled with the absence of any caspase-orthologs in
Plasmodium,18 the range of inhibitors was extended to
elucidate the preferred substrate specificity of the target
protease. Besides CA-074, all the tested inhibitors prevented
the increase of CaspaTag-positive cells in CQ-induced
samples (Figure 6a). Inhibition by clan CA-specific inhibitor
E64d showed that target proteases were clan CA cysteine
proteases. Inhibition by z-Phe-Ala-fmk (zFA), z-Phe-Phe-fmk
(zFF) and z-Leu-Leu-Leu-fmk (zLLL) showed that target
proteases lack the P1-aspartate specificity characteristic of
caspases, and suggests the involvement of clan CA
proteases such as cathepsins and calpain-like proteases in
the pathway. Cathepsin B-specific CA-074 was unable to
fully prevent CaspaTag binding, suggesting that cathepsin
B-like proteases are partly involved in mediating the pathway.
Hoechst staining of DNA content. To verify the
effectiveness of the extended panel of inhibitors, parasites
were assayed for a loss of DNA content 10 h after CQ treat-
ment. Healthy ring-stage parasites were used to distinguish
the G1 population (Supplementary data, Figure S7A) and a
control experiment excluded the possibility that CQ compe-
ted with Hoechst DNA-binding (Supplementary data, Figure
S7C). Finally, flow cytometry histograms and fluorescence
microscopy images (Supplementary data, Figure S7B and D)
were compared to characterize parasite cultures that had
been subject to various experimental conditions.
CQ-treated parasites showed an increased proportion of
cells with sub-G1 DNA content from 10 to over 20%
(Figure 6b). The effect of different inhibitors corroborated
findings of the previous section, suggesting that clan CA
proteases are essential in mediators for DNA degradation in
CQ-induced PCD and that cathepsin B-like proteases act in
concert with other clan CA mediators to give rise to DNA
breakdown.
Intracellular calcium studies. In healthy parasites, calcium
indicator fluo-4-AM localized to the digestive vacuole (DV) of
healthy parasites (Supplementary data, Figure S8).
However, CQ treatment resulted in a redistribution of
Ca2þ to the cytoplasm in a dose-dependent manner
(Supplementary data, Figure S8 and S9). To explore the
possibility that MOMP is Ca2þ -mediated, a cell-permeable
calcium chelator, BAPTA-AM, was used but this did not
significantly reduce the proportion of CQ-induced parasites
undergoing MOMP (Supplementary data, Figure S10).
Inter-strain comparisons for JC1 and Hoechst loss. We
subsequently assayed for PCD features in CQ-resistant 7G8
and K1 strains (Figure 7). The IC50 values of CQ in 7G8 and
K1 parasites were determined to be 76 and 202 nM,
respectively (Supplementary Data, Figure S1B and S1C).
Pretreatment with VP lowered the IC50 values of 7G8 and K1
to 61 and 120 nM, respectively. Interestingly, 7G8 cultures
mirrored 3D7 and showed a significant drop in the JC1-
positive population at concentrations of CQ exceeding 3 mM
of CQ (Figure 7a). In comparison, the drop in JC1-positive K1
cells was markedly less at this same concentration, and it
was only at a higher concentration of the drug that there was
a significant decrease in the proportion of JC1-positive cells.
However, pretreatment of K1 with 10 mM of chemoreversal
agent VP resulted in a significant decrease in JC1-positive
cells even at 3mM of CQ.
As with 3D7, both 7G8 and K1 showed a significant
increase in the proportion of parasites with sub-G1 DNA
content after CQ treatment (Figure 7b). However, these
proportions were significantly lower than those observed in
3D7. Although VP pretreatment was able to significantly
increase the proportion of K1 parasites with sub-G1 DNA
content, this reversion was incomplete. It should be noted that
BD LSRII showed better resolution of Hoechst-positive
parasites from the uninfected RBC population, and conse-
quently the proportion of cells showing DNA loss as measured
by this cytometer was slightly greater than that measured in
the previous set of experiments using DAKO cytomation.
Discussion
Our results show that both CQ and ST treatment gives rise
to features of PCD in Plasmodium including MOMP, the
activation of cysteine proteases and in situ DNA fragmenta-
tion. These findings corroborate growing evidence supporting
the existence of PCD hallmarks in parasites induced by a
variety of agents including drugs,8,19 febrile temperatures,19–20
exposure to bilirubin resulting in reactive oxygen species
increase9 and binding of platelets to infected erythrocytes.21
Observation of apoptotic features such as chromatin
condensation, DNA fragmentation, phosphatidylserine expo-
sure, apoptotic body formation and caspase activity have
been shown by Al-Olayan et al.5 in the mosquito midgut stage
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of P. berghei. However, this could not be reproduced by
Le Chat et al.22 In apoptotic P. falciparum, as induced by
drugs and heat-shock treatments, Nyakeriga et al.6 and Totino
et al.7 were unable to detect MOMP, DNA fragmentation and
laddering, or chromatin cleavage. In contrast, Meslin et al.8
and Kumar et al.9 showed MOMP, DNA fragmentation,
chromatin condensation and DEVDase activity in other strains
of P. falciparum induced by similar stimuli. Still other authors
observed evidence of autophagy or secondary necrosis
including cytoplasmic vacuolation in drug-resistant strains
such as PSS1 or a swelling of the food vacuole in CSC-1.7,19
These discrepancies may be due to differing drug concentra-
tions, parasite strains, developmental stages, inducers and
assaying methods, complicating the conclusions that can be
reliably discerned.
Another limitation of the existing studies has been the
absence of definitive evidence outlining any pathway of PCD.
As unicellular eukaryotes may display more than one PCD
pathway,23 the focus of this study was primarily to delineate
the pathway induced by CQ.
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Several established MOMP inhibitors were investigated
(data not shown) and 4HT was shown to inhibit MOMP
in CQ-induced cells without significantly reducing the
proportion of healthy cells in the control group. Current
evidence suggests that 4HT inhibits Ca2þ -induced MOMP in
ischemic myocardiocytes by binding to Ca2þ -activated
Kþ channels of the mitochondria.24–25 However, this is not
likely to be the mechanism of action in the parasite as
preincubation of parasites with the Ca2þ chelator BAPTA-AM
did not prevent MOMP. In addition to 4HT, the effectiveness
of zVAD in inhibiting MOMP in CQ-induced cells points clearly
toward the activity of cysteine proteases being upstream
of MOMP.
Despite some toxicity, 4HT was also able to partially reduce
the major proportion of CaspaTag-positive cells in CQ-treated
cultures, suggesting that MOMP occurs upstream of the bulk
of cysteine protease activation in CQ-treated cells. This
conclusion was supported by time course experiments that
showed MOMP occurring in a significant proportion of cells at
4 h after CQ induction, whereas the increase in CaspaTag-
positive cells was only significant after 6 h.
Pretreatment with 4HT was unable to prevent CQ-induced
DNA fragmentation. Instead, 4HT toxicity made it difficult to
interpret findings. In contrast, zVAD pretreatment clearly
reduced TUNEL staining in CQ-induced cells, placing the
activation of cysteine proteases upstream of in situ DNA
fragmentation.
The effectiveness of zVAD’s inhibition of cysteine pro-
teases, leading to a concomitant change in the proportion of
CQ-induced parasites showing MOMP, cysteine protease
activity and DNA fragmentation, is strongly indicative of a
regulated pathway linking these PCD features. In addition, the
effect of 4HT in reducing CaspaTag-positive cells and time
point experiments provides further insight into the CQ-induced
pathway outlined below (Diagram 1b). Our model of
CQ-induced PCD suggests that the activity of cysteine
proteases is necessary for the loss of mitochondrial mem-
brane potential. This preceding event is likely to be involved in
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Figure 7 Drug-resistant parasites showing different PCD phenotype profiles. (a)
Cultures of chloroquine-sensitive 3D7 and chloroquine-resistant 7G8 and K1 show
different levels of JC1 loss at different concentrations of the drug. VPþK1 culture
consisted of K1 parasites preincubated with 10 mM of verapamil (VP) for 30min
before chloroquine treatments. Data represent means±S.E. (AvB and AvC,
Po0.001; BvD and DvF, Po0.01; AvE, Po0.05; N¼ 3). (b) 3D7, 7G8 and K1
parasites showing different proportion of cells with sub-G1 DNA content as
measured by Hoechst staining. Data represent means±S.E. (AvB, AvC, BvD and
DvC, Po0.001; DvE, Po0.01; CvE, Po0.05; N¼ 3)
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Figure 6 (a) CaspaTag staining of chloroquine-induced Plasmodium falciparum
parasites pretreated with inhibitors. Percentage of CaspaTag-positive cells
preincubated for 30min with the following: Vehicle control; 50 mM zVAD.fmk,
zDEVD.fmk and CA-074; 5 mM of zFA.fmk, zFF.fmk and zLLL.fmk; 12.5mM of
E64d. Thereafter, cells were subjected to 8-h treatment with vehicle control ,
30mM chloroquine . Data represent means±S.E. (AvB, Po0.001; BvC,
Po0.01; AvC, P¼ 0.054; N¼ 3) (b) Hoechst staining of parasites showing sub-G1
DNA content. The proportion of cells with weak Hoechst staining was assayed for
10 h after treatment with or without 30mM chloroquine. Cultures had been
pretreated for 30min with the following: Vehicle control; 50 mM zVAD.fmk,
zDEVD.fmk and CA-074; 5 mM of zFA.fmk, zFF.fmk and zLLL.fmk; 12.5mM of
E64d. Weak Hoechst staining was indicative of DNA degradation corresponding to a
loss of DNA content leading to the sub-G1 population. Data represent means
±S.E. (AvB and AvC, Po0.001; BvC, Po0.05; N¼ 3)
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the amplification of protease activity, which results in DNA
fragmentation. As experiments with 4HT were complicated by
its toxicity, we cannot exclude the possibility that this
amplification of the cysteine proteases can occur indepen-
dently of mitochondrial permeabilization.
Our CQ-induced PCD model resembles the classical model
of receptor-mediated apoptosis, which was recently reviewed
by Degterev and Yuan.23 Although caspase 8 is able to
directly activate executioner caspase 3 to initiate apoptosis,
this process is greatly amplified through the mitochondrial
route (Diagram 1a).
Although these models display overall similarities in the
assayed characteristics, the absence of caspase homologs
and classical mediators of apoptosis, such as Bid, Bax, AIF,
a Classical Apoptotic Pathway: 
c Proposed Plasmodium falciparum Programmed Cell Death Model: 
b Proposed PCD Model in 3D7 and CQ-resistant 7G8 and K1: 
Low levels of
Caspase- 8 MOMP DNA fragmentationCaspase-3Fas-L: Fas
3D7+ CQ MOMP Cys Protease(s) Cys Protease(s) DNA frag/loss 
7G8 + CQ MOMP Cys Protease(s) Cys Protease(s) DNA frag/loss 
K1 + CQ MOMPCys Protease(s) Cys Protease(s) DNA frag/loss
VP VP
DV swelling,
partially
permeabilized
Clan CA cysteine
proteases leak
from DV
MOMP
Others? 
Massive release of
digestive enzymes
and Clan CA
proteases to cytosol
DNA degradation
and loss
zVAD 4HT
zVAD
Cyt c?
ROS?
High-dose CQ
localizes to DV
DV
permeabilized
PfCRT VP
Diagram 1 (a) In the classical apoptotic pathway of mammalian cells, Fas-ligand binding to its receptor results in the activation of low levels of caspase 8. Caspase 8 then
results in a series of events leading to MOMP and the release of proapoptotic factors. These factors form the apoptosome with caspase 9 and elicit a strong caspase 3
response, ultimately inducing DNA fragmentation. (b) In 3D7 P. falciparum parasites treated with chloroquine (CQ), similar cell death features are observed. Inhibition studies
with zVAD.fmk (zVAD) and 4-hydroxytamoxifen (4HT) suggest that CQ treatment results in the activation of low levels of cysteine proteases, which triggers mitochondria outer
membrane permeabilization (MOMP). In turn, this results in an increase in the amount of cysteine activity, which causes DNA degradation. This ordered sequence of events is
characteristic of a programmed cell death pathway. This pathway is also likely to exist in CQ-resistant 7G8 parasites. Although showing similar proportions of cells with MOMP
as 3D7, 7G8 parasites have a lesser degree of DNA degradation, suggesting that there are differences in the later-stage events of the pathway. In CQ-resistant K1 parasites,
differences in both the degree of MOMP and DNA degradation suggest that the earlier stages of the pathway may differ from 3D7. The effectiveness of verapamil in reducing
these differences shows the importance of CQ localization to the digestive vacuole (DV) in this pathway. Taken together with the results of other studies, a more detailed model
of PCD in P. falciparum is proposed. (c) Only at high doses of CQ does the drug accumulate in the DV to an extent that causes the DV to swell and become partially
permeabilized. Clan CA proteases that are abundant in the DV leak into the cytoplasm of the parasite, resulting in the dysregulation of the mitochondrion. This places further
stress on the DV leading to its rupture and a release of its contents (more clan CA proteases and other hydrolytic enzymes), which degrades the DNA and eventually the
parasite
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Apaf-1 and Bcl-2 proteins, alludes to different mediators being
involved in the process of CQ-induced PCD inP. falciparum.26
In ST-induced cells, the ineffectiveness of zVAD and 4HT in
reducing PCD features suggests that a different phenomenon
is being observed. The high concentrations of ST may have
resulted in unregulated necrosis that is unlikely to be
prevented by any number of inhibitors.27
An apparent limitation of this study is the high concentra-
tions of CQ used. In an attempt to consolidate competing
findings by different studies using different drug concentra-
tions (35 nM–100 mM),6–8,19 parasites in this study were
initially exposed to a range of drug concentrations (30,
300 nM, 3 and 30 mM) of CQ for 8 h and observed for features
of PCD. To ensure that parasites were all still in a comparable
trophozoite stage of development, an incubation time
exceeding 10 h was not considered. As a significant loss of
Dcm and an increase in CaspaTag-positive cells were
observed only with 3 and 30 mM of CQ treatment, the latter
dose was used. These parameters worked optimally with
our protocols and allowed the investigation of multiple
PCD phenotypes at a single time point. Moreover, effective
zVAD-mediated inhibition of PCD features even at such high
doses of CQ suggests that key modulators of a well-regulated
pathway are indeed being targeted.
Conclusions on studies using micromolar concentrations of
CQ must not be projected as the primary mechanism of CQ’s
antimalarial activity. At physiological nanomolar concentra-
tions, lysosomotropic CQ accumulates in the DV and
interferes with hemazoin formation.28 However, our findings
showed the drug being present in the cytoplasm of the
parasite at micromolar concentrations where it could bind
nonselectively to unknown cytosolic PCD mediators. Alter-
natively, relocalization of the drug at a high dose could be due
to the excessive accumulation of the lysosomotropic drug in
the DV leading to its compromise, the acidification of the
cytoplasm and the accumulation of protonated CQ inside the
entire parasite.
To exclude the possibility that the proposed CQ-induced
PCD pathway is an unregulated necrotic event, two necrosis
controls were included. Both sodium azide and heat treat-
ments resulted in distinctly different cell death profiles
compared with CQ-induced cultures. Moreover, it was clearly
shown that zVAD was unable to modulate the extent of cell
death features, strongly suggesting that these necrosis controls
were genuinely undergoing an unregulated and disordered cell
death. The ineffectiveness of zVAD in limiting necrotic cell
death has been previously shown29–30 and contrasts with
the well-ordered ‘programmed’ pathway characterized in
CQ-induced cells where downstream features of cell death
can clearly be inhibited by 4HT and zVAD.
Although the concentration of the CQ used limits this
study’s usefulness in understanding the therapeutic mechan-
isms of CQ’s antimalarial activity, the objective of discovering
novel mediators of P. falciparum PCD is not undermined. As
further research characterizes what takes place in the
parasite at such a dose of CQ, novel compounds specifically
targeting the mediators of this PCD pathway may be optimally
designed for antimalarial use.
Unlike the mammalian model, the identities of participating
cysteine proteases in CQ-induced P. falciparum remains
unknown, given the conspicuous absence of classical
apoptotic mediators. Meslin et al.8 have suggested that a
clan CD protease PfMCA1 (a metacaspase homolog) was
a likely mediator of cell death in P. falciparum. However,
Le Chat et al.22 showed that P. berghei metacaspases did not
have a role in PCD.
There is growing evidence that caspase inhibitors with fmk
or aldehyde reactive groups (including CaspaTag) are not as
specific as once believed, but can efficiently inhibit non-
caspase cysteine proteases including metacaspases, cal-
pains and cathepsins.10,14,17 This nonspecific nature of zVAD
binding in our study is confirmed by the fact that other fmk
moiety-containing inhibitors with different amino-acid
sequences (z-Asp-Glu-Val-Asp-fmk (zDEVD), zFA, zFF and
zLLL) seemed equally effective in reducing CaspaTag
binding. Moreover, zFA, zFF and zLLL do not have the
aspartate residue at the P1 position that is essential for
classical caspase binding. Although the nonspecific nature of
zVAD binding has allowed us to characterize the aforemen-
tioned pathway, we cannot ascertain the identity of its target
protease on the basis of its binding to zVAD alone. Thus, clan
CA-specific inhibitors such as E64d and CA-074 were
included as well.
Despite being a broad-acting inhibitor of clan CA cysteine
proteases, E64d does not crossreact with clan CD pro-
teases.17,31–33 As E64d was effective at inhibiting CaspaTag
binding and DNA loss in CQ-induced cells, we concluded that
clan CA proteases are essential mediators of CQ-induced
PCD. In addition, as CaspaTag binds both Clan CA and CD
proteases, and Clan CA-specific E64d completely prevented
the increase in CaspaTag-positive cells, this suggests that
clan CA mediators are likely to be the proteases accounting
for the cysteine protease activity being detected. The partial
inhibition of PCD features by specific cathepsin B inhibitor,
CA-074, shows that there may be multiple pathways involving
clan CA proteases. Nevertheless, it would be premature to
exclude the involvement of clan CD proteases such as
PfMCA1 as regulators or even key downstream mediators of
CQ-induced PCD.
Conventionally, Clan CD caspases mediate apoptosis.
However, recent work highlights the importance of clan CA
papain-like proteases such as calpains and cathepsins in
PCD regulation through truncation of Bid or activation of Bax,
leading to MOMP.34–36 Even though Bid and Bax homologs do
not exist in the parasite, it is conceivable that one or more
parasite clan CA proteases may function likewise to cleave
a novel parasite-specific mediator of MOMP. Clan CA
proteases are well associated with parasites and include
cathepsins and falcipains from the C1 family and calpains
from the C2 family.17 P. falciparum 3D7 possesses a
preprocathepsin C homolog, a calpain homolog, four falci-
pains, SERA (serine-repeat antigens) and other uncharacter-
ized C1 proteases.18
Interestingly, a study by Gazarini et al.37 showed that
micromolar quantities of CQ triggered calcium release from
acidic compartments of P. chabaudi. Moreover, Farias et al.38
observed that calcium release was accompanied by a
detection of cysteine-protease activity in the cytoplasm of
P. chabaudi and P. falciparum. Although the authors suggest
calpain involvement, this is unlikely as putative calpain
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homologs in Plasmodium do not have a calcium-binding
domain.14 Our own studies on 3D7 also showed a relocaliza-
tion of Ca2þ from the DV of the parasite to the cytoplasm.
However, the use of the calcium chelator, BAPTA-AM, did
not inhibit MOMP in CQ-induced parasites. However, the
role of Ca2þ in limiting other features of CQ-induced PCD
has yet to be fully investigated and it is still possible that
in CQ-induced PCD, cysteine protease are activated in
a Ca2þ -dependent mechanism as these authors have
suggested.
This CQ-induced PCD pathway would only be of interest to
drug developers if its existence were also established in
CQ-resistant strains of P. falciparum. As such, drug-resistant
7G8 and K1 were also investigated for features of PCD. CQ
resistance was initially believed to arise from mutations in
the DV transmembrane protein CQ-resistance transporter
(PfCRT).39 Two distinct sets of mutations were found, one
originating from South America and the other from Southeast
Asia and Africa. These mutations in PfCRT allow the efflux of
CQ from its primary site of action, the DV, thereby conferring
resistance to the drug. Interestingly, this resistance, originat-
ing from the Asia-Africa mutations, was shown to be reversible
by VP and similarly structured compounds.40
Despite the differences between 7G8 and K1 in PfCRT
mutation sets, both strains showed a significant proportion of
cells with JC1-1 loss and DNA degradation, suggesting that
PCD pathways exist even in these resistant strains. Interest-
ingly, 7G8 showed a similar extent of cells exhibiting MOMP
as 3D7 but a lower proportion of cells with sub-G1 content,
even at higher CQ concentrations. In comparison, K1 showed
a VP-reversible reduction in the proportion of cells with MOMP
and DNA degradation that was only detectable at higher CQ
levels. These findings show the importance of PfCRT and
CQ’s localization in the DV for PCD to occur (Diagram 1b). In
addition, the lesser extent of PCD features even at high CQ
concentrations suggests that these CQ-resistant strains may
have a reduced propensity to undergo PCD. This model for
drug resistance has also been established in cancer cells
where treatment pressure leads to a selection of clones with
altered apoptotic machinery or regulatory components.41
Such cells are more likely to survive and may be cross-
resistant to other drugs using the apoptotic pathway. Although
further work on field isolates and other PCD inducers are
needed, the potential of finding a link between drug resistance
and resistance to cell death in P. falciparum would be very
illuminating.
In summary, our present study not only shows that CQ and
ST treatments give rise to characteristic features of PCD, but
also a linear pathway implicating mitochondrial dysregulation,
clan CA cysteine protease activity and DNA fragmentation
is evident after CQ-induction. Although no specific mediators
have been identified at this juncture, we have determined
clan CA proteases as key pathway modulators. In addition,
we have shown that PCD features exist in drug-resistant
7G8 and K1 parasites, and are suitable for therapeutic
exploits. Besides providing promising targets for therapeutic
drugs, breakthroughs in this area of PCD modulators should
also enable a greater understanding of drug resistance
and the physiological role of PCD pathways in unicellular
organisms.
Materials and methods
Parasite culture. A CQ-sensitive laboratory strain of P. falciparum, 3D7
(MRA-102, MR4, ATCC, Manassas, Va, USA), and CQ-resistant strains 7G8 (MRA-
154, MR4, ATCC) and K1 (MRA-159, MR4, ATCC) were cultured continuously with
minor modifications to the method previously described.42 Parasite cultures were
maintained in 75 or 125 cm2 flasks using malaria culture media (MCM) consisting of
RPMI 1640 supplemented with 0.5% (w/v) albumax I (Invitrogen, Auckland, New Zealand),
0.005% (w/v) hypoxanthine, 0.03% (w/v) L-glutamate, 0.25% (w/v) gentamycin and 2.5%
human erythrocytes. Flasks were gassed with 3%CO2, 4%O2 and 93%N2 and incubated
at 371C in a dark incubator. Culture medium was replenished during subculturing
on alternate days. Thin Giemsa smears were made to determine parasitemia before
subculture and at the start of each experiment. Sorbitol synchronization was carried
out weekly to select for ring-stage parasites.43 Saponin enrichment was carried out
before staining with CaspaTag and TUNEL assay to liberate the parasites from
host erythrocytes.44 Cultures of approximately 7–10% parasitemia were used,
with parasites being in the late-ring stage (22–26 h post-invasion) during the
administration of inhibitor and drugs, unless otherwise stated.
Drug preparation and treatments. CQ diphosphate (Sigma-Aldrich,
Dorset, UK) was dissolved in PBS and filter-sterilized to obtain working solutions
of 300mM, and stored in the dark at 41C. A new batch of CQ working solution was
made before each experiment. Unless otherwise stated, parasitized erythrocytes
were incubated for 8 or 10 h in 30mM of CQ and washed twice with MCM before
assaying for apoptotic features. Staurosporine (ST, Sigma-Aldrich) stock solution
(1 mM) was prepared by dissolving the drug in filtered dimethylsulfoxide (DMSO)
and stored at 201C. Working concentrations of ST at 100mM were prepared
before each experiment by diluting the stock solution with MCM. Infected
erythrocytes were treated for 8 or 10 h with 10 mM ST, and washed twice with MCM
before cell death assays. For necrosis controls, cultures were incubated with either
0.1% (w/v) of sodium azide for 8 or 10 h, or heat treated at 501C for 1 h, and then
incubated at 371C for 8 or 10 h. Verapamil (VP, Sigma-Aldrich) was dissolved in
PBS with 0.5% acetic acid, to a working concentration of 1 mM, and parasite
cultures were pretreated with 10 mM of VP for 30min before adding CQ. Vehicle
controls consisted of equivalent amounts of DMSO or acetic acid.
Synthesis of CM-CQ. Under a standard synthetic procedure,45 using flame-
dried glass apparatus under nitrogen atmosphere, des(N-ethyl)-CQ (25.0mg,
0.09 mmol), that is, N-(7-chloro-4-quinolinyl)-N 0-ethyl-1,4-diaminobutane,46 was
dissolved in anhydrous acetonitrile (5.0 ml). Finely powdered and predried
potassium carbonate (24.8mg, 0.2 mmol) was then added, followed by the
addition of an anhydrous acetonitrile solution (1.0 ml) of the known CM
a-bromoester (44.2mg, 0.1 mmol), that is, 2-bromo-N-(2-(2-(7-(dimethylamino)-2-
oxo-2H-chromen-4-yl)acetamido)ethyl)-acetamide.16 The mixture was stirred for
13 h at room temperature, then filtered and the filtrate evaporated to give a yellow
residue. The residue was then purified by flash column chromatography (230–400
mesh silica gel) to give CM-CQ (45.0mg, 0.074mmol) in 82% yield.
NMR measurements of CM-CQ were recorded on a 300MHz (for 1H) and 500MHz
(for 13C) Bruker spectrometer (Fallanden, Switzerland) fitted with a pulse-field gradient
probe. The residual resonance of deuterated solvents was used as an internal reference.
1H NMR (300MHz, MeOD) d: 0.87 (t, J¼ 6.4 Hz, 3H), 1.52–1.57 (m, 2H), 1.62–1.74
(m, 2H), 2.41 (t, J¼ 7.0 Hz, 2H), 2.49 (q, J¼ 7.0 Hz, 2H), 2.97 (bs, 8H), 3.21
(m, 2H), 3.38–3.40 (m, 4H), 3.63 (s, 2H), 5.98 (s, 1H), 6.34 (d, J¼ 2.3 Hz, 1H), 6.43
(d, J¼ 5.8 Hz, 1H), 6.55 (dd, J¼ 2.6 Hz, 9.1 Hz, 1H), 7.25 (dd, J¼ 2.0 Hz, 8.8 Hz,
1H), 7.42 (d, J¼ 8.8 Hz, 1H), 7.71 (d, J¼ 2.0 Hz, 1H), 7.99 (d, J¼ 9.1 Hz, 1H), 8.29
(d, J¼ 5.8 Hz, 1H). 13C NMR (125MHz, MeOD): d 12.1, 26.2, 27.1, 40.0, 40.1,
40.2, 44.0, 47.4, 50.0, 55.7, 58.7, 98.6, 99.6, 109.7, 110.3, 110.5, 118.7, 124.5,
125.8, 126.8, 127.3, 136.2, 149.4, 152.2, 152.7, 154.6, 157.1, 164.2, 171.5, 175.2.
Analytical HPLC and mass spectrometry of CM-CQ was carried out on a
Shimadzu LC-IT-TOF system (Kyoto, Japan) equipped with an autosampler, using
a reverse-phase Phenomenex Luna (Torrance, CA, USA) 5 mm C18, 50 3.0 mm
column. Solvent mixtures of 0.1% TFA/H2O (solvent-A) and 0.1% TFA/CH3CN
(solvent-B) were used as coeluents under a linear gradient of 1–100% of solvent B
(over 45min; flow rate of 0.5 ml/min). This gave a purity of CM-CQ of 98% with a
found m/z [Mþ 1] of 607.277 (calculated for C32H39ClN6O4: 607.280).
Inhibitor preparation and treatments. Inhibitors were all purchased from
Sigma-Aldrich, dissolved in manufacturer’s recommended solvents to stock
concentrations and stored at 201C. Working solutions were obtained by diluting
the stock concentration with MCM just before administration. Parasite cultures were
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preincubated with inhibitors for 30min before drug treatment. The final inhibitor
concentrations were as follows: 4HT, 20 mM; zVAD, zDEVD and CA-074, 50mM;
zFA, zFF and zLLL, 5 mM; E64d, 12.5mM; BAPTA-AM, 1–50 mM. Lower
concentrations of zFA, zFF and zLLL were used because of their poor solubility.
Vehicle control consisted of equivalent amounts of DMSO and/or ethanol in
accordance with solvent amounts used in various inhibitor treatments.
Mitochondria transmembrane potential assay. Cell-permeable lipophilic
cation probe JC-1 (Molecular Probes, Eugene, OR, USA), also known as 5,50, 6,60-
tetrachloro-1,10,3,30-tetraethyl-benzimidazolylcarbocyanine iodine, normally has green
fluorescence (525 nm) but aggregates at high transmembrane potential of functional
mitochondria to emit an orange-red fluorescence (excitation maximum at 590 nm).47
A final concentration of 6mM of JC-1 was added to 0.5ml of treated parasitized
erythrocytes and incubated at 371C in a dark humidified candle jar for 30min.
Cells were washed twice with PBS and resuspended to the original volume before
being analyzed by flow cytometry. Percentage of JC1(Red)/JC1(Green) ratios were
obtained to determine the extent of mitochondrial dysregulation as per the
manufacturer’s recommendations.
Cysteine protease activity assay. CaspaTag pancaspase in situ assay kit,
sulforhodamine (Chemicon, Temecula, CA, USA), consists of a membrane-permeable
fluoromethyl ketone inhibitor of caspases conjugated to sulforhodamine (SR-VAD-fmk).
Saponin enrichment was performed on 2ml of treated cells, washed twice with 2ml
PBS and resuspended in 300ml MCM. In accordance with the manufacturer’s
instructions, each vial of CaspaTag was dissolved in 50ml DMSO to produce the
CaspaTag stock solution (150 ) and stored in the dark at 201C Before staining,
further dilutions were made using MCM till a working solution of 30 CaspaTag was
obtained. To each sample, 7ml of the freshly prepared CaspaTag reagent was added
and the culture incubated at 371C in the dark for 1 h. Thereafter, two washes were
carried out with 1ml of the wash buffer provided. The samples were resuspended in
1ml of wash buffer before flow cytometry analysis.
In situ DNA fragmentation assay. ApoDirect DNA Fragmentation Assay kit
(Clontech, San Diego, CA, USA) is a TUNEL (terminal deoxynucleotidyltransferase
dUTP nicked-end labeling) assay that makes use of FITC-conjugated dUTP incorporation
into nicked DNA by means of terminal deoxynucleotidyltransferase. Saponin enrichment
of 2ml of the treated cells also permeabilized the parasite’s plasma membrane to the
contents of the TUNEL stain. Parasites were then spun down and washed twice with
1ml of wash buffer provided in the kit. Samples were then resuspended in 50 ml of
the premixed staining solution, as directed by the manufacturer, and incubated in
the dark for 90min at 371C. Samples were then washed twice in 1 ml of rinse buffer
and resuspended in 1ml of PBS before flow cytometry.
Hoechst staining of parasite DNA content. Hoechst 33342 stain
(provided together with CaspaTag kit, Chemicon) is a lipophilic DNA-binding
fluorescent stain that is excited by ultraviolet light (350 nm), and emits blue
fluorescence light (461 nm). After the parasite cultures were incubated in the
absence/presence of drugs/inhibitors for 10 h, cells were washed twice with PBS
and 2 ml of the 200mg/ml stain was added per 1 ml of culture for 30min. The cells
were then washed twice and resuspended in PBS before flow cytometry.
Intracellular calcium detection. Cell-permeable Fluo-4-AM (Molecular
Probes) fluoresces green when bound with Ca2þ and was used to detect
intracellular calcium stores. A final concentration of 2mM of FLuo-4-AM was added
to 0.5 ml of treated parasitized erythrocytes and incubated at 371C in a dark
humidified candle jar for 30min. Cells were washed twice with PBS and
resuspended to the original volume before viewing under a confocal microscope. At
least 30 parasitized cells were counted for each condition.
Inhibitory concentration (IC50) determination. Parasitized cultures
(ring stage) diluted with fresh erythrocytes and MCM to 2% parasitemia and
1.25% hematocrit were incubated with various concentrations of commercial
CQ (Sigma, Dorset, UK), CM (i.e., 7-dimethylamino-4-coumarinacetic acid) and
CM-CQ for 48 h. To determine parasitemia, cultures were stained with Hoechst
33342, as described above, and analyzed by flow cytometry.
Flow cytometric analyses. Cell numbers and fluorescence intensity after
staining with JC-1, CaspaTag, FITC-dUTP or Hoechst were assayed by a flow cytometer
(DAKOCytomation Cyan ADP, Fort Collins, CO, USA), equipped with an argon-ion laser
tuned to 488 nm and a violet laser tuned to 405 nm. Blue, green and red fluorescence
was detected using 450, 525 and 595 nm band-pass filters, respectively. For experiments
involving 7G8 and K1, a high-throughput flow cytometer (BD LSRII Special Order
System, San Jose, CA, USA) was used to manage the large number of samples
involved. Using BD LSR II, JC-1 stain was excited with 488 nm blue laser with
green fluorescence being detected using the 505LP 525/50BP filter, whereas red
fluorescence was detected using the 570LP 585/42BP filter. For Hoechst stain,
excitation was by the 355 nm UV laser, whereas detection used the 450LP 450/
50BP filter. Both flow cytometers were adjusted for forward and side scattering to
accommodate either infected erythrocytes or liberated parasites. Between 100 000
and 200 000 erythrocytes or 10 000–20 000 enriched parasites were analyzed from
each sample and its respective duplicate to ensure reliability. At least three
independent experiments were performed unless otherwise stated.
Fluorescence and confocal microscopy. For fluorescence microscopy,
wet mounts of stained infected erythrocytes or enriched parasites were observed
using an image analysis setup consisting of a light and fluorescence microscope
(Olympus BX60, Japan) coupled to a microscope digital camera (Olympus DP71,
Tokyo, Japan) and images were captured using computer software DP Manager
version 3.1.1.208 (Olympus). Confocal imaging was performed using Olympus
Fluoview FV1000 (Japan) equipped with solid state and argon ion lasers tuned
to 405 and 488 nm, respectively. Images were captured using Olympus Fluoview
version 1.6b. For enumeration purposes, images of at least 50 parasitized erythrocytes
were screened per concentration of drug used.
Statistical analyses. All data shown are means±S.E.M. Statistical
difference between percentages of stained cells was measured using univariate
t-test for means and comparisons between multiple groups were analyzed using
ANOVA and post hoc comparison using Tukey’s test for paired comparisons.
Significantly different results (Po0.05) were highlighted.
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